Journals / Uluslararası Hematoloji-Onkoloji Dergisi / 2015 / Cilt: 25 - Sayı: 1

Kronik Myeloid Lösemi Hücrelerinin Metotreksat ve Suberoylanilide Hidroksamikasitin Sinerjetik Etkisi ile Apoptoza Sürüklenmesi

Synergistic Effects of Methotrexate and Suberoylanilide Hydroxamic Acid in Triggering Apoptosis of Chronic Myeloid Leukemia Cells

Pages
1–11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We suggest that combination of MTX and SAHA may minimize the toxicity and side effects of SAHA treatment, thus providing lower amounts of each drug in CML treatment.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In this study, we have investigated the effects of suberoylanilide hydroxamic acid (SAHA) against chronic myeloid leukemia (CML) cells in combination studies with methotrexate (MTX), which is a dihydrofolate reductase inhibitor used in combination therapy with other agents or alone.
📊
Key Findings & Data:Combination of synergistic ratios of MTX and SAHA led to apoptotic cell death of CML cells via PARP cleavage, cytochrome c release and ROS increase in vitro.
💡
Conclusion & Impact:We suggest that combination of MTX and SAHA may minimize the toxicity and side effects of SAHA treatment, thus providing lower amounts of each drug in CML treatment.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

In this study, we have investigated the effects of suberoylanilide hydroxamic acid (SAHA) against chronic myeloid leukemia (CML) cells in combination studies with methotrexate (MTX), which is a dihydrofolate reductase inhibitor used in combination therapy with other agents or alone. Combination of synergistic ratios of MTX and SAHA led to apoptotic cell death of CML cells via PARP cleavage, cytochrome c release and ROS increase in vitro. We suggest that combination of MTX and SAHA may minimize the toxicity and side effects of SAHA treatment, thus providing lower amounts of each drug in CML treatment.

Özet

MTX, tek başına veya diğer ajanlarla kombine tedavide kullanılan bir dihidrofolat redüktaz inhibitörüdür. Bu çalışmada kronik myeloid lösemi (K562) hücrelerine karşı metotreksat (MTX) ile birlikte kullanılan suberoylanilide hidroksamik asit (SAHA)’nın etkilerini araştırdık. MTX ve SAHA’nın sinerjetik oranları, K562 hücrelerinde in vitro kesilmiş PARP’a , sitokrom c salınımına ve ROS artışı ile apoptotik hücre ölümüne neden oldu. K562 tedavisinde MTX ve SAHA’nın kombinasyonunun her bir ilacın daha düşük dozlarının kullanılmasını sağlayacağını ve böylece SAHA’nın yan etkilerinin ve toksisitesinin azaltılabileceğini düşünmekteyiz.

🔖

Cite This Article

ALTUNDAG, E. M., YILMAZ, A. M., COREK, C., YALÇIN, A. S., TAGA, Y., KOÇTÜRK, A. S. (2015). Kronik Myeloid Lösemi Hücrelerinin Metotreksat ve Suberoylanilide Hidroksamikasitin Sinerjetik Etkisi ile Apoptoza Sürüklenmesi. Uluslararası Hematoloji-Onkoloji Dergisi, Cilt: 25 - Sayı: 1, 1–11. https://ajindex.com/articles/322826

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Hehlmann R, Berger U, Hochhaus A. Chronic myeloid leukemia: a model for oncology. Ann Hematol 84: 487-497, 2005.
  2. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 96: 3343-3356, 200 Gesbert F, Griffin JD. Bcr/Abl activates transcription of the Bcl-X gene through STAT5. Blood 96: 2269-2276, 2000.
  3. Gojo I, Jiemjit A, Trepel JB, et al. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 109: 2781-2790, 2007.
  4. Zhang B, Strauss AC, Chu S, et al. Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer Cell 17(5): 427–442, 2010.
  5. Richon VM, Sandhoff TW, Rifkind RA, et al. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 97: 10014-10019, 2000.
  6. Sambucetti LC, Fischer DD, Zabludoff S, et al. Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J Biol Chem 274: 34940-34947, 1999.
  7. Yu C, Rahmani M, Almenara J, et al. Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571- sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells. Cancer Res 63: 2118-2126, 2003.
  8. Butler LM, Agus DB, Scher HI, et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 60: 5165-5170, 2000.
  9. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92: 1210-1216, 2000.
  10. Parbin S, Kar S, Shilpi A, et al. Histone Deacetylases: A saga of perturbed acetylation homeostasis in cancer. J Histochem Cytochem 62: 11-33, 2014.
  11. Nimmanapalli R, Fuino L, Stobaugh C, et al. Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood 101: 3236-3239, 2003.
  12. Fiskus W, Pranpat M, Bali P, et al. Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells. Blood 108: 645-652, 2006.
  13. McLaughlin F, La Thangue NB F. Histone deacetylase inhibitors open new doors in cancer therapy. Biochem